

Dave Singh

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1877667/dave-singh-publications-by-citations.pdf>

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

358 papers	14,739 citations	59 h-index	110 g-index
446 ext. papers	18,601 ext. citations	7.3 avg, IF	6.85 L-index

#	Paper	IF	Citations
358	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 195, 557-582	10.2	1682
357	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. <i>European Respiratory Journal</i> , 2019 , 53,	13.6	722
356	Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. <i>New England Journal of Medicine</i> , 2018 , 378, 1671-1680	59.2	511
355	The nuclear receptor REV-ERB α mediates circadian regulation of innate immunity through selective regulation of inflammatory cytokines. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 582-7	11.5	409
354	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. <i>European Respiratory Journal</i> , 2017 , 49,	13.6	398
353	Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. <i>Lancet, The</i> , 2018 , 391, 1076-1084	40	300
352	Blood Eosinophils: A Biomarker of Response to Extrafine Beclomethasone/Formoterol in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015 , 192, 523-5	10.2	273
351	Eosinophilic inflammation in COPD: prevalence and clinical characteristics. <i>European Respiratory Journal</i> , 2014 , 44, 1697-700	13.6	257
350	Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β_2 -agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. <i>Lancet, The</i> , 2016 , 388, 963-73	40	256
349	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. <i>Archivos De Bronconeumologia</i> , 2017 , 53, 128-149	0.7	247
348	Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. <i>Lancet, The</i> , 2017 , 389, 1919-1929	40	235
347	Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. <i>Respirology</i> , 2017 , 22, 575-601	3.6	228
346	Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Respiratory Medicine, the</i> , 2021 , 9, 196-206	35.1	219
345	The effect of inhaled IFN- γ on worsening of asthma symptoms caused by viral infections. A randomized trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014 , 190, 145-54	10.2	182
344	Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management. <i>Lancet, The</i> , 2015 , 385, 1789-1798	40	168
343	Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. <i>European Respiratory Journal</i> , 2012 , 40, 830-6	13.6	148
342	Non-invasive phenotyping using exhaled volatile organic compounds in asthma. <i>Thorax</i> , 2011 , 66, 804-9	7.3	140

341	Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study. <i>BMC Pulmonary Medicine</i> , 2014 , 14, 178	3.5	138
340	Tiotropium + olodaterol shows clinically meaningful improvements in quality of life. <i>Respiratory Medicine</i> , 2015 , 109, 1312-9	4.6	122
339	Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD. <i>New England Journal of Medicine</i> , 2020 , 383, 35-48	59.2	121
338	Selective inducible nitric oxide synthase inhibition has no effect on allergen challenge in asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007 , 176, 988-93	10.2	113
337	Sputum neutrophils as a biomarker in COPD: findings from the ECLIPSE study. <i>Respiratory Research</i> , 2010 , 11, 77	7.3	111
336	Exploring the relevance and extent of small airways dysfunction in asthma (ATLANTIS): baseline data from a prospective cohort study. <i>Lancet Respiratory Medicine</i> , 2019 , 7, 402-416	35.1	108
335	Non-invasive metabolomic analysis of breath using differential mobility spectrometry in patients with chronic obstructive pulmonary disease and healthy smokers. <i>Analyst, The</i> , 2010 , 135, 315-20	5	106
334	MUC5B is the major mucin in the gel phase of sputum in chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008 , 178, 1033-9	10.2	104
333	Inhaled corticosteroids in COPD: friend or foe?. <i>European Respiratory Journal</i> , 2018 , 52,	13.6	102
332	Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial. <i>International Journal of COPD</i> , 2012 , 7, 503-13	3	100
331	Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials. <i>Lancet Respiratory Medicine</i> , 2013 , 1, 714-27	35.1	98
330	Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease. <i>Journal of Allergy and Clinical Immunology</i> , 2018 , 141, 2037-2047.e10	11.5	95
329	Benralizumab for the Prevention of COPD Exacerbations. <i>New England Journal of Medicine</i> , 2019 , 381, 1023-1034	59.2	94
328	Identification of cells expressing IL-17A and IL-17F in the lungs of patients with COPD. <i>Chest</i> , 2011 , 139, 1089-1100	5.3	92
327	CD4-regulatory cells in COPD patients. <i>Chest</i> , 2007 , 132, 156-63	5.3	90
326	Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. <i>Lancet Respiratory Medicine</i> , 2019 , 7, 745-756	35.1	85
325	LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis. <i>International Journal of COPD</i> , 2017 , 12, 907-922	3	85
324	Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT). <i>Respiratory Research</i> , 2015 , 16, 92	7.3	85

323	alpha,beta-Unsaturated aldehydes contained in cigarette smoke elicit IL-8 release in pulmonary cells through mitogen-activated protein kinases. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2009 , 296, L839-48	5.8	83
322	Electronic cigarette exposure triggers neutrophil inflammatory responses. <i>Respiratory Research</i> , 2016 , 17, 56	7.3	80
321	Inhibition of the asthmatic allergen challenge response by the CRTH2 antagonist OC000459. <i>European Respiratory Journal</i> , 2013 , 41, 46-52	13.6	77
320	Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trial. <i>Lancet Respiratory Medicine</i> , 2018 , 6, 499-510	35.1	74
319	The pathology of small airways disease in COPD: historical aspects and future directions. <i>Respiratory Research</i> , 2019 , 20, 49	7.3	73
318	Azithromycin for Acute Exacerbations of Asthma : The AZALEA Randomized Clinical Trial. <i>JAMA Internal Medicine</i> , 2016 , 176, 1630-1637	11.5	73
317	Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials. <i>Lancet, The</i> , 2019 , 394, 1737-1749	4.0	73
316	Blood and sputum eosinophils in COPD; relationship with bacterial load. <i>Respiratory Research</i> , 2017 , 18, 88	7.3	72
315	The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma. <i>Respiratory Research</i> , 2010 , 11, 26	7.3	72
314	Biomarkers of systemic inflammation and depression and fatigue in moderate clinically stable COPD. <i>Respiratory Research</i> , 2011 , 12, 3	7.3	71
313	Impulse oscillometry in COPD: identification of measurements related to airway obstruction, airway conductance and lung volumes. <i>Respiratory Medicine</i> , 2009 , 103, 136-43	4.6	70
312	A phase 1 study evaluating the pharmacokinetics, safety and tolerability of repeat dosing with a human IL-13 antibody (CAT-354) in subjects with asthma. <i>BMC Pulmonary Medicine</i> , 2010 , 10, 3	3.5	69
311	The Axl receptor tyrosine kinase is a discriminator of macrophage function in the inflamed lung. <i>Mucosal Immunology</i> , 2015 , 8, 1021-1030	9.2	68
310	Increased phosphorylated p38 mitogen-activated protein kinase in COPD lungs. <i>European Respiratory Journal</i> , 2013 , 42, 28-41	13.6	68
309	Sputum microbiome temporal variability and dysbiosis in chronic obstructive pulmonary disease exacerbations: an analysis of the COPDMAP study. <i>Thorax</i> , 2018 , 73, 331-338	7.3	67
308	A randomized, placebo-controlled study of the effects of the p38 MAPK inhibitor SB-681323 on blood biomarkers of inflammation in COPD patients. <i>Journal of Clinical Pharmacology</i> , 2010 , 50, 94-100	2.9	67
307	The effect of peroxisome proliferator-activated receptor- α ligands on in vitro and in vivo models of COPD. <i>European Respiratory Journal</i> , 2014 , 43, 409-20	13.6	66
306	Exhaled volatile organic compounds for phenotyping chronic obstructive pulmonary disease: a cross-sectional study. <i>Respiratory Research</i> , 2012 , 13, 72	7.3	65

305	Cigarette smoke and its component acrolein augment IL-8/CXCL8 mRNA stability via p38 MAPK/MK2 signaling in human pulmonary cells. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2012 , 303, L929-38	5.8	65
304	The prevalence of small airways disease in adult asthma: A systematic literature review. <i>Respiratory Medicine</i> , 2016 , 116, 19-27	4.6	64
303	Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020 , 201, 1508-1516	10.2	63
302	Predictors of objective cough frequency in chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013 , 187, 943-9	10.2	62
301	Identification of lipocalin and apolipoprotein A1 as biomarkers of chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010 , 181, 1049-60	10.2	60
300	Depression and its relationship with poor exercise capacity, BODE index and muscle wasting in COPD. <i>Respiratory Medicine</i> , 2009 , 103, 1572-9	4.6	59
299	A comparison of lung function methods for assessing dose-response effects of salbutamol. <i>British Journal of Clinical Pharmacology</i> , 2004 , 58, 134-41	3.8	57
298	The use of plethysmography and oscillometry to compare long-acting bronchodilators in patients with COPD. <i>British Journal of Clinical Pharmacology</i> , 2008 , 65, 244-52	3.8	55
297	Identification and functional analysis of SKA2 interaction with the glucocorticoid receptor. <i>Journal of Endocrinology</i> , 2008 , 198, 499-509	4.7	55
296	Magnitude of umeclidinium/vilanterol lung function effect depends on monotherapy responses: Results from two randomised controlled trials. <i>Respiratory Medicine</i> , 2016 , 112, 65-74	4.6	54
295	Increased airway T regulatory cells in asthmatic subjects. <i>Chest</i> , 2010 , 138, 905-12	5.3	53
294	Pulmonary inflammation in patients with chronic obstructive pulmonary disease with higher blood eosinophil counts. <i>Journal of Allergy and Clinical Immunology</i> , 2017 , 140, 1181-1184.e7	11.5	52
293	A comparison of exhaled nitric oxide measurements performed using three different analysers. <i>Respiratory Medicine</i> , 2006 , 100, 1392-6	4.6	52
292	Impaired Mitochondrial Microbicidal Responses in Chronic Obstructive Pulmonary Disease Macrophages. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 196, 845-855	10.2	51
291	Cigarette smoke extract induced cytokine and chemokine gene expression changes in COPD macrophages. <i>Cytokine</i> , 2008 , 42, 205-216	4	50
290	New combination bronchodilators for chronic obstructive pulmonary disease: current evidence and future perspectives. <i>British Journal of Clinical Pharmacology</i> , 2015 , 79, 695-708	3.8	49
289	Chronic Obstructive Pulmonary Disease Biomarkers and Their Interpretation. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019 , 199, 1195-1204	10.2	49
288	Characterisation of lung macrophage subpopulations in COPD patients and controls. <i>Scientific Reports</i> , 2017 , 7, 7143	4.9	48

287	Genetics of sputum gene expression in chronic obstructive pulmonary disease. <i>PLoS ONE</i> , 2011 , 6, e243957	3.7	48
286	Induced sputum genes associated with spirometric and radiological disease severity in COPD ex-smokers. <i>Thorax</i> , 2011 , 66, 489-95	7.3	48
285	Unfractionated heparin inhibits live wild type SARS-CoV-2 cell infectivity at therapeutically relevant concentrations. <i>British Journal of Pharmacology</i> , 2021 , 178, 626-635	8.6	48
284	Airway host-microbiome interactions in chronic obstructive pulmonary disease. <i>Respiratory Research</i> , 2019 , 20, 113	7.3	47
283	Current Controversies in the Pharmacological Treatment of Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016 , 194, 541-9	10.2	47
282	Neutrophil chemotaxis caused by chronic obstructive pulmonary disease alveolar macrophages: the role of CXCL8 and the receptors CXCR1/CXCR2. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013 , 347, 173-80	4.7	47
281	Efficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studies. <i>International Journal of COPD</i> , 2010 , 5, 197-208	3	47
280	Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol. <i>International Journal of COPD</i> , 2016 , 11, 1413-24	3	47
279	Increased ACE2 Expression in Bronchial Epithelium of COPD Patients who are Overweight. <i>Obesity</i> , 2020 , 28, 1586-1589	8	46
278	Safety of indacaterol in the treatment of patients with COPD. <i>International Journal of COPD</i> , 2011 , 6, 477-92	3	46
277	Goals of COPD treatment: Focus on symptoms and exacerbations. <i>Respiratory Medicine</i> , 2020 , 166, 105938	3.8	44
276	Activin Type II Receptor Blockade for Treatment of Muscle Depletion in Chronic Obstructive Pulmonary Disease. A Randomized Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019 , 199, 313-320	10.2	44
275	Characterisation and impact of reported and unreported exacerbations: results from ATTAIN. <i>European Respiratory Journal</i> , 2014 , 44, 1156-65	13.6	44
274	Inhibition of lipopolysaccharide-stimulated chronic obstructive pulmonary disease macrophage inflammatory gene expression by dexamethasone and the p38 mitogen-activated protein kinase inhibitor	4.7	44
273	COPD phenotype description using principal components analysis. <i>Respiratory Research</i> , 2009 , 10, 41	7.3	44
272	Phase 2, randomised placebo-controlled trial to evaluate the efficacy and safety of an anti-GM-CSF antibody (KB003) in patients with inadequately controlled asthma. <i>BMJ Open</i> , 2016 , 6, e007709	3	43
271	Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial. <i>BMC Pulmonary Medicine</i> , 2015 , 15, 91	3.5	42
270	Differential Effects of p38, MAPK, PI3K or Rho Kinase Inhibitors on Bacterial Phagocytosis and Efferocytosis by Macrophages in COPD. <i>PLoS ONE</i> , 2016 , 11, e0163139	3.7	41

269	Identification of airway mucosal type 2 inflammation by using clinical biomarkers in asthmatic patients. <i>Journal of Allergy and Clinical Immunology</i> , 2017 , 140, 710-719	11.5	40
268	Opsonic Phagocytosis in Chronic Obstructive Pulmonary Disease Is Enhanced by Nrf2 Agonists. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018 , 198, 739-750	10.2	40
267	The effect of electronic cigarette and tobacco smoke exposure on COPD bronchial epithelial cell inflammatory responses. <i>International Journal of COPD</i> , 2018 , 13, 989-1000	3	40
266	Pharmacological strategies to reduce exacerbation risk in COPD: a narrative review. <i>Respiratory Research</i> , 2016 , 17, 112	7.3	39
265	Increased levels of soluble interleukin-6 receptor and CCL3 in COPD sputum. <i>Respiratory Research</i> , 2014 , 15, 103	7.3	38
264	Altered gene expression in blood and sputum in COPD frequent exacerbators in the ECLIPSE cohort. <i>PLoS ONE</i> , 2014 , 9, e107381	3.7	38
263	Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 , 203, 553-564	10.2	38
262	Inhaled corticosteroid containing combinations and mortality in COPD. <i>European Respiratory Journal</i> , 2018 , 52,	13.6	36
261	The reproducibility of COPD blood eosinophil counts. <i>European Respiratory Journal</i> , 2018 , 52,	13.6	35
260	Emphysema- and airway-dominant COPD phenotypes defined by standardised quantitative computed tomography. <i>European Respiratory Journal</i> , 2016 , 48, 92-103	13.6	35
259	Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies. <i>Lancet Respiratory Medicine</i> , 2020 , 8, 158-170	35.1	35
258	Loss of glucocorticoid receptor expression by DNA methylation prevents glucocorticoid induced apoptosis in human small cell lung cancer cells. <i>PLoS ONE</i> , 2011 , 6, e24839	3.7	34
257	The repeatability of interleukin-6, tumor necrosis factor-alpha, and C-reactive protein in COPD patients over one year. <i>International Journal of COPD</i> , 2009 , 4, 149-56	3	34
256	Genetic control of gene expression at novel and established chronic obstructive pulmonary disease loci. <i>Human Molecular Genetics</i> , 2015 , 24, 1200-10	5.6	33
255	Blood Eosinophil Counts in Clinical Trials for Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020 , 202, 660-671	10.2	33
254	Effects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO studies. <i>Respiratory Research</i> , 2016 , 17, 73	7.3	33
253	Time of Day Affects Eosinophil Biomarkers in Asthma: Implications for Diagnosis and Treatment. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018 , 198, 1578-1581	10.2	33
252	Extrafine beclomethasone/formoterol compared to fluticasone/salmeterol combination therapy in COPD. <i>BMC Pulmonary Medicine</i> , 2014 , 14, 43	3.5	32

251	Reduced glucocorticoid receptor expression and function in airway neutrophils. <i>International Immunopharmacology</i> , 2012 , 12, 26-33	5.8	32
250	Assessing Short-term Deterioration in Maintenance-naïve Patients with COPD Receiving Umeclidinium/Vilanterol and Tiotropium: A Pooled Analysis of Three Randomized Trials. <i>Advances in Therapy</i> , 2017 , 33, 2188-2199	4.1	31
249	Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD. <i>Respiratory Research</i> , 2019 , 20, 180	7.3	31
248	Perception of symptoms and quality of life - comparison of patients and physicians' views in the COPD MIRROR study. <i>International Journal of COPD</i> , 2017 , 12, 2189-2196	3	31
247	The effects of corticosteroids on COPD lung macrophages: a pooled analysis. <i>Respiratory Research</i> , 2015 , 16, 98	7.3	30
246	Anti-inflammatory potential of PI3K and JAK inhibitors in asthma patients. <i>Respiratory Research</i> , 2016 , 17, 124	7.3	29
245	Oral and inhaled p38 MAPK inhibitors: effects on inhaled LPS challenge in healthy subjects. <i>European Journal of Clinical Pharmacology</i> , 2015 , 71, 1175-84	2.8	28
244	Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized, double-blind, phase 2 studies. <i>Pulmonary Pharmacology and Therapeutics</i> , 2018 , 48, 71-79	3.5	28
243	Non-invasive biomarkers and pulmonary function in smokers. <i>International Journal of COPD</i> , 2008 , 3, 171-83	3	28
242	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. <i>Archivos De Bronconeumologia</i> , 2017 , 53, 128-149	0.7	27
241	Influence of lung CT changes in chronic obstructive pulmonary disease (COPD) on the human lung microbiome. <i>PLoS ONE</i> , 2017 , 12, e0180859	3.7	27
240	RV568, a narrow-spectrum kinase inhibitor with p38 MAPK and -selectivity, suppresses COPD inflammation. <i>European Respiratory Journal</i> , 2017 , 50,	13.6	26
239	The sputum microbiome is distinct between COPD and health, independent of smoking history. <i>Respiratory Research</i> , 2020 , 21, 183	7.3	26
238	Clinical characteristics of eosinophilic COPD versus COPD patients with a history of asthma. <i>Respiratory Research</i> , 2017 , 18, 73	7.3	25
237	LPS challenge in healthy subjects: an investigation of neutrophil chemotaxis mechanisms involving CXCR1 and CXCR2. <i>International Immunopharmacology</i> , 2012 , 13, 225-31	5.8	25
236	Inhaled LPS challenges in smokers: a study of pulmonary and systemic effects. <i>British Journal of Clinical Pharmacology</i> , 2012 , 74, 1023-32	3.8	25
235	Down regulation of T cell receptor expression in COPD pulmonary CD8 cells. <i>PLoS ONE</i> , 2013 , 8, e71629	3.7	25
234	COVID-19 and COPD: a narrative review of the basic science and clinical outcomes. <i>European Respiratory Review</i> , 2020 , 29,	9.8	25

233	Attached stratified mucus separates bacteria from the epithelial cells in COPD lungs. <i>JCI Insight</i> , 2018 , 3,	9.9	25
232	Circadian rhythm of exhaled biomarkers in health and asthma. <i>European Respiratory Journal</i> , 2019 , 54,	13.6	24
231	Efficacy and safety of nebulized glycopyrrolate for administration using a high efficiency nebulizer in patients with chronic obstructive pulmonary disease. <i>British Journal of Clinical Pharmacology</i> , 2015 , 79, 492-500	3.8	24
230	Toll-like receptor 3 blockade in rhinovirus-induced experimental asthma exacerbations: A randomized controlled study. <i>Journal of Allergy and Clinical Immunology</i> , 2018 , 141, 1220-1230	11.5	24
229	Feasibility and challenges of using multiple breath washout in COPD. <i>International Journal of COPD</i> , 2018 , 13, 2113-2119	3	24
228	The short-term bronchodilator effects of the dual phosphodiesterase 3 and 4 inhibitor RPL554 in COPD. <i>European Respiratory Journal</i> , 2018 , 52,	13.6	24
227	Feasibility assessment of using oxygen-enhanced magnetic resonance imaging for evaluating the effect of pharmacological treatment in COPD. <i>European Journal of Radiology</i> , 2014 , 83, 2093-101	4.7	23
226	T lymphocyte insensitivity to corticosteroids in chronic obstructive pulmonary disease. <i>Respiratory Research</i> , 2012 , 13, 20	7.3	23
225	Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol. <i>Respiratory Research</i> , 2017 , 18, 106	7.3	23
224	Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide. <i>International Journal of COPD</i> , 2017 , 12, 2917-2928	3	23
223	The role of the liver X receptor in chronic obstructive pulmonary disease. <i>Respiratory Research</i> , 2013 , 14, 106	7.3	23
222	Chronic Obstructive Pulmonary Disease Individualized Therapy: Tailored Approach to Symptom Management. <i>Advances in Therapy</i> , 2017 , 34, 281-299	4.1	22
221	CRTH2 antagonists in asthma: current perspectives. <i>Clinical Pharmacology: Advances and Applications</i> , 2017 , 9, 165-173	1.5	22
220	The Eva study: aims and strategy. <i>European Respiratory Journal</i> , 2012 , 40, 823-9	13.6	22
219	Effect of 12 weeks of once-daily tiotropium/olodaterol on exercise endurance during constant work-rate cycling and endurance shuttle walking in chronic obstructive pulmonary disease. <i>Therapeutic Advances in Respiratory Disease</i> , 2018 , 12, 1753465818755091	4.9	21
218	A trial of beclomethasone/formoterol in COPD using EXACT-PRO to measure exacerbations. <i>European Respiratory Journal</i> , 2013 , 41, 12-7	13.6	21
217	Inflammatory Endotype-associated Airway Microbiome in Chronic Obstructive Pulmonary Disease Clinical Stability and Exacerbations: A Multicohort Longitudinal Analysis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 , 203, 1488-1502	10.2	21
216	The stability of blood Eosinophils in chronic obstructive pulmonary disease. <i>Respiratory Research</i> , 2020 , 21, 15	7.3	20

215	Mechanisms of corticosteroid insensitivity in COPD alveolar macrophages exposed to NTHi. <i>Respiratory Research</i> , 2017 , 18, 61	7.3	20
214	The modulatory effects of the PDE4 inhibitors CHF6001 and roflumilast in alveolar macrophages and lung tissue from COPD patients. <i>Cytokine</i> , 2019 , 123, 154739	4	20
213	The effects of dexamethasone on cigarette smoke induced gene expression changes in COPD macrophages. <i>International Immunopharmacology</i> , 2010 , 10, 57-64	5.8	20
212	Corticosteroid insensitive alveolar macrophages from asthma patients; synergistic interaction with a p38 mitogen-activated protein kinase (MAPK) inhibitor. <i>British Journal of Clinical Pharmacology</i> , 2015 , 79, 756-66	3.8	19
211	The Effect of Fatigue and Fatigue Intensity on Exercise Tolerance in Moderate COPD. <i>Lung</i> , 2016 , 194, 889-895	2.9	19
210	Extrafine beclometasone dipropionate/formoterol fumarate: a review of its effects in chronic obstructive pulmonary disease. <i>Npj Primary Care Respiratory Medicine</i> , 2016 , 26, 16030	3.2	19
209	A Disintegrin and Metalloproteinase Domain-8: A Novel Protective Proteinase in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018 , 198, 1254-1267	10.2	19
208	Novel anti-inflammatory agents in COPD: targeting lung and systemic inflammation. <i>Current Drug Targets</i> , 2013 , 14, 235-45	3	19
207	Systematic literature review of patient-reported outcome measures used in assessment and measurement of sleep disorders in chronic obstructive pulmonary disease. <i>International Journal of COPD</i> , 2015 , 10, 293-307	3	18
206	Diesel exhaust particle exposure in vitro alters monocyte differentiation and function. <i>PLoS ONE</i> , 2012 , 7, e51107	3.7	18
205	Characterization of TLR-induced inflammatory responses in COPD and control lung tissue explants. <i>International Journal of COPD</i> , 2016 , 11, 2409-2417	3	18
204	Change in blood eosinophils following treatment with inhaled corticosteroids may predict long-term clinical response in COPD. <i>European Respiratory Journal</i> , 2020 , 55,	13.6	17
203	A dose-ranging study of the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in COPD. <i>Respiratory Research</i> , 2020 , 21, 47	7.3	17
202	The effects of repeated Toll-like receptors 2 and 4 stimulation in COPD alveolar macrophages. <i>International Journal of COPD</i> , 2018 , 13, 771-780	3	17
201	Whole-blood cultures from renal-transplant patients stimulated ex vivo show that the effects of cyclosporine on lymphocyte proliferation are related to P-glycoprotein expression. <i>Transplantation</i> , 2004 , 77, 557-61	1.8	17
200	A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6 µg and 160/18/9.6 µg using co-suspension delivery technology in moderate-to-very severe COPD: The ETHOS study protocol. <i>Respiratory Medicine</i> , 2019 , 158, 59-66	4.6	16
199	Ampicillin resistance in from COPD patients in the UK. <i>International Journal of COPD</i> , 2017 , 12, 1507-1513	3	16
198	PI3K, p38 and JAK/STAT signalling in bronchial tissue from patients with asthma following allergen challenge. <i>Biomarker Research</i> , 2018 , 6, 14	8	16

197	A Disintegrin and A Metalloproteinase-9 (ADAM9): A Novel Proteinase Culprit with Multifarious Contributions to COPD. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018 ,	10.2	16
196	Rhinovirus-16 induced temporal interferon responses in nasal epithelium links with viral clearance and symptoms. <i>Clinical and Experimental Allergy</i> , 2019 , 49, 1587-1597	4.1	16
195	Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. <i>Respiratory Research</i> , 2007 , 8, 52	7.3	16
194	Tuberculin test measurement: variability due to the time of reading. <i>Chest</i> , 2002 , 122, 1299-301	5.3	16
193	Blood eosinophil count and airway epithelial transcriptome relationships in COPD versus asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020 , 75, 370-380	9.3	16
192	Randomized controlled trials and real-world observational studies in evaluating cardiovascular safety of inhaled bronchodilator therapy in COPD. <i>International Journal of COPD</i> , 2016 , 11, 2885-2895	3	16
191	Small Airway Disease in Patients with Chronic Obstructive Pulmonary Disease. <i>Tuberculosis and Respiratory Diseases</i> , 2017 , 80, 317-324	3.2	15
190	Additive anti-inflammatory effects of corticosteroids and phosphodiesterase-4 inhibitors in COPD CD8 cells. <i>Respiratory Research</i> , 2016 , 17, 9	7.3	15
189	The bronchodilator effects of extrafine glycopyrronium added to combination treatment with beclometasone dipropionate plus formoterol in COPD: A randomised crossover study (the TRIDENT study). <i>Respiratory Medicine</i> , 2016 , 114, 84-90	4.6	15
188	Differential anti-inflammatory effects of budesonide and a p38 MAPK inhibitor AZD7624 on COPD pulmonary cells. <i>International Journal of COPD</i> , 2018 , 13, 1279-1288	3	15
187	The effect of the novel phosphodiesterase-4 inhibitor MEM 1414 on the allergen induced responses in mild asthma. <i>BMC Pulmonary Medicine</i> , 2014 , 14, 166	3.5	15
186	Effect of AeroChamber Plus [®] on the lung and systemic bioavailability of beclometasone dipropionate/formoterol pMDI. <i>British Journal of Clinical Pharmacology</i> , 2011 , 72, 932-9	3.8	15
185	Tolerability of high cumulative doses of the HFA modulate beclomethasone dipropionate/formoterol combination inhaler in asthmatic patients. <i>Pulmonary Pharmacology and Therapeutics</i> , 2008 , 21, 551-7	3.5	15
184	Bacteria and sputum inflammatory cell counts; a COPD cohort analysis. <i>Respiratory Research</i> , 2020 , 21, 289	7.3	15
183	The Effect of Inhaled Corticosteroid Withdrawal and Baseline Inhaled Treatment on Exacerbations in the IMPACT Study. A Randomized, Double-Blind, Multicenter Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020 , 202, 1237-1243	10.2	14
182	P38 MAPK and glucocorticoid receptor crosstalk in bronchial epithelial cells. <i>Journal of Molecular Medicine</i> , 2020 , 98, 361-374	5.5	14
181	Do inhaled corticosteroid/long-acting beta2-agonist fixed combinations provide superior clinical benefits compared with separate inhalers? A literature reappraisal. <i>Allergy and Asthma Proceedings</i> , 2012 , 33, 140-4	2.6	14
180	Repeat tuberculin testing in BCG-vaccinated subjects in the United Kingdom. The booster effect varies with the time of reading. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2001 , 164, 962-4	10.2	14

179	A phase 1/1b study of PUR1900, an inhaled formulation of itraconazole, in healthy volunteers and asthmatics to study safety, tolerability and pharmacokinetics. <i>British Journal of Clinical Pharmacology</i> , 2020 , 86, 723-733	3.8	14
178	Blood eosinophils as a biomarker of future COPD exacerbation risk: pooled data from 11 clinical trials. <i>Respiratory Research</i> , 2020 , 21, 240	7.3	14
177	Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA. <i>International Journal of COPD</i> , 2019 , 14, 531-546	3	13
176	COPD monocytes demonstrate impaired migratory ability. <i>Respiratory Research</i> , 2017 , 18, 90	7.3	13
175	Gene expression changes caused by the p38 MAPK inhibitor dilmapiomod in COPD patients: analysis of blood and sputum samples from a randomized, placebo-controlled clinical trial. <i>Pharmacology Research and Perspectives</i> , 2015 , 3, e00094	3.1	13
174	Characterization of the inflammatory response to inhaled lipopolysaccharide in mild to moderate chronic obstructive pulmonary disease. <i>British Journal of Clinical Pharmacology</i> , 2015 , 79, 767-76	3.8	13
173	Reduced exhaled breath condensate pH in asthmatic smokers using inhaled corticosteroids. <i>Respirology</i> , 2009 , 14, 419-23	3.6	13
172	Evaluation of glucocorticoid receptor function in COPD lung macrophages using beclomethasone-17-monopropionate. <i>PLoS ONE</i> , 2013 , 8, e64257	3.7	13
171	A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19. <i>European Respiratory Journal</i> , 2021 , 58,	13.6	13
170	Neutral sphingomyelinase-2, acid sphingomyelinase, and ceramide levels in COPD patients compared to controls. <i>International Journal of COPD</i> , 2016 , 11, 2139-2147	3	13
169	Leukotriene B4 levels in sputum from asthma patients. <i>ERJ Open Research</i> , 2016 , 2,	3.5	13
168	Effects of the Toll-like receptor 7 (TLR7) agonist, AZD8848, on allergen-induced responses in patients with mild asthma: a double-blind, randomised, parallel-group study. <i>Respiratory Research</i> , 2019 , 20, 288	7.3	13
167	An Evaluation Of Single And Dual Long-Acting Bronchodilator Therapy As Effective Interventions In Maintenance Therapy-Naïve Patients With COPD. <i>International Journal of COPD</i> , 2019 , 14, 2835-2848	3	13
166	Sputum and blood transcriptomics characterisation of the inhaled PDE4 inhibitor CHF6001 on top of triple therapy in patients with chronic bronchitis. <i>Respiratory Research</i> , 2020 , 21, 72	7.3	12
165	The Human Virome Protein Cluster Database (HVPC): A Human Viral Metagenomic Database for Diversity and Function Annotation. <i>Frontiers in Microbiology</i> , 2018 , 9, 1110	5.7	12
164	Corticosteroid effects on COPD alveolar macrophages: dependency on cell culture methodology. <i>Journal of Immunological Methods</i> , 2014 , 405, 144-53	2.5	12
163	The effects of corticosteroids on cytokine production from asthma lung lymphocytes. <i>International Immunopharmacology</i> , 2014 , 23, 581-4	5.8	12
162	A phase 2 study to evaluate the safety, efficacy and pharmacokinetics of DP2 antagonist GB001 and to explore biomarkers of airway inflammation in mild-to-moderate asthma. <i>Clinical and Experimental Allergy</i> , 2020 , 50, 189-197	4.1	12

161	Inhaled corticosteroids and COVID-19-related mortality: confounding or clarifying?. <i>Lancet Respiratory Medicine</i> , 2020, 8, 1065-1066	35.1	12
160	Type 2 inflammation in eosinophilic chronic obstructive pulmonary disease. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 1861-1864	9.3	12
159	Comparative effectiveness of triple therapy dual bronchodilation in COPD. <i>ERJ Open Research</i> , 2019, 5,	3.5	12
158	Therapeutic index of inhaled corticosteroids in asthma: A dose-response comparison on airway hyperresponsiveness and adrenal axis suppression. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 483-493	3.8	12
157	Predicting Corticosteroid Response in Chronic Obstructive Pulmonary Disease. Blood Eosinophils Gain Momentum. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 1098-1100	10.2	11
156	A Randomized Trial of Dual-Acting Bronchodilator AZD8871 for Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 1282-1284	10.2	11
155	Clinical characteristics of COPD patients with tidal expiratory flow limitation. <i>International Journal of COPD</i> , 2017, 12, 1503-1506	3	11
154	Blood eosinophil counts in COPD patients compared to controls. <i>European Respiratory Journal</i> , 2019, 54,	13.6	11
153	Characteristics and longitudinal progression of chronic obstructive pulmonary disease in GOLD B patients. <i>BMC Pulmonary Medicine</i> , 2017, 17, 42	3.5	11
152	MR Quantitative Equilibrium Signal Mapping: A Reliable Alternative to CT in the Assessment of Emphysema in Patients with Chronic Obstructive Pulmonary Disease. <i>Radiology</i> , 2015, 275, 579-88	20.5	11
151	A dose-ranging study of the bronchodilator effects of abediterol (LAS100977), a long-acting β -adrenergic agonist, in asthma; a Phase II, randomized study. <i>BMC Pulmonary Medicine</i> , 2014, 14, 176	3.5	11
150	A comparison of the clinical and induced sputum characteristics of early- and late-onset asthma. <i>Lung</i> , 2012, 190, 459-62	2.9	11
149	Asthma control and COPD symptom burden in patients using fixed-dose combination inhalers (SPRINT study). <i>Npj Primary Care Respiratory Medicine</i> , 2020, 30, 1	3.2	11
148	Increased type 2 inflammation post rhinovirus infection in patients with moderate asthma. <i>Cytokine</i> , 2020, 125, 154857	4	11
147	The development and first validation of the Manchester Early Morning Symptoms Index (MEMSI) for patients with COPD. <i>Thorax</i> , 2015, 70, 757-63	7.3	10
146	Measuring disease activity in COPD: is clinically important deterioration the answer?. <i>Respiratory Research</i> , 2020, 21, 134	7.3	10
145	CRAC channel inhibition produces greater anti-inflammatory effects than glucocorticoids in CD8 cells from COPD patients. <i>Clinical Science</i> , 2014, 126, 223-32	6.5	10
144	Efficacy of Tiotropium/Olodaterol Compared with Tiotropium as a First-Line Maintenance Treatment in Patients with COPD Who Are Naïve to LAMA, LABA and ICS: Pooled Analysis of Four Clinical Trials. <i>Advances in Therapy</i> , 2020, 37, 4175-4189	4.1	10

143	Efficacy and safety of CHF6001, a novel inhaled PDE4 inhibitor in COPD: the PIONEER study. <i>Respiratory Research</i> , 2020 , 21, 246	7.3	10
142	The novel inhaled glucocorticoid receptor agonist GW870086X protects against adenosine-induced bronchoconstriction in asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2015 , 136, 501-2.e6	11.5	9
141	COPD sputum eosinophils: relationship to blood eosinophils and the effect of inhaled PDE4 inhibition. <i>European Respiratory Journal</i> , 2020 , 56,	13.6	9
140	Stability of eosinophilic inflammation in COPD bronchial biopsies. <i>European Respiratory Journal</i> , 2020 , 56,	13.6	9
139	Reduced risk of clinically important deteriorations by ICS in COPD is eosinophil dependent: a pooled post-hoc analysis. <i>Respiratory Research</i> , 2020 , 21, 17	7.3	9
138	Anti-inflammatory effects of the phosphodiesterase type 4 inhibitor CHF6001 on bronchoalveolar lavage lymphocytes from asthma patients. <i>Cytokine</i> , 2019 , 113, 68-73	4	9
137	Weighing the evidence for pharmacological treatment interventions in mild COPD; a narrative perspective. <i>Respiratory Research</i> , 2019 , 20, 141	7.3	9
136	Repeatability of induced sputum measurements in moderate to severe asthma. <i>Respiratory Medicine</i> , 2014 , 108, 1566-8	4.6	9
135	Resistome analyses of sputum from COPD and healthy subjects reveals bacterial load-related prevalence of target genes. <i>Thorax</i> , 2020 , 75, 8-16	7.3	9
134	Treatment response to indacaterol/glycopyrronium versus salmeterol/fluticasone in exacerbating COPD patients by gender: a post-hoc analysis in the FLAME study. <i>Respiratory Research</i> , 2019 , 20, 4	7.3	9
133	The effect of exacerbation history on outcomes in the IMPACT trial. <i>European Respiratory Journal</i> , 2020 , 55,	13.6	9
132	An investigation of the anti-inflammatory effects and a potential biomarker of PI3K inhibition in COPD T cells. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2017 , 44, 932-940	3	8
131	Relief of methacholine-induced bronchospasm with extrafine beclomethasone dipropionate/formoterol in comparison with salbutamol in asthma. <i>Pulmonary Pharmacology and Therapeutics</i> , 2012 , 25, 392-8	3.5	8
130	Inhibition of the early asthmatic response to inhaled allergen by the 5-lipoxygenase activating protein inhibitor GSK2190915: a dose-response study. <i>International Journal of General Medicine</i> , 2013 , 6, 897-903	2.3	8
129	The effects of smoking on the lipopolysaccharide response and glucocorticoid sensitivity of alveolar macrophages of patients with asthma. <i>Chest</i> , 2009 , 136, 163-170	5.3	8
128	Effects of corticosteroids on COPD lung macrophage phenotype and function. <i>Clinical Science</i> , 2020 , 134, 751-763	6.5	8
127	Composite endpoints in COPD: clinically important deterioration in the UPLIFT trial. <i>Respiratory Research</i> , 2020 , 21, 177	7.3	8
126	Multi-omics links IL-6 trans-signalling with neutrophil extracellular trap formation and infection in COPD. <i>European Respiratory Journal</i> , 2021 , 58,	13.6	8

125	Lung microbiome composition and bronchial epithelial gene expression in patients with COPD versus healthy individuals: a bacterial 16S rRNA gene sequencing and host transcriptomic analysis.. <i>Lancet Microbe, The</i> , 2021 , 2, e300-e310	22.2	8
124	Current Controversies in Chronic Obstructive Pulmonary Disease. A Report from the Global Initiative for Chronic Obstructive Lung Disease Scientific Committee. <i>Annals of the American Thoracic Society</i> , 2019 , 16, 29-39	4.7	8
123	Inhaled long-acting muscarinic antagonists in asthma - A narrative review. <i>European Journal of Internal Medicine</i> , 2021 , 85, 14-22	3.9	8
122	Extrafine triple therapy in patients with symptomatic COPD and history of one moderate exacerbation. <i>European Respiratory Journal</i> , 2019 , 53,	13.6	7
121	Determinants of response to inhaled extrafine triple therapy in asthma: analyses of TRIMARAN and TRIGGER. <i>Respiratory Research</i> , 2020 , 21, 285	7.3	7
120	Bronchodilator efficacy of extrafine glycopyrronium bromide: the Glyco 2 study. <i>International Journal of COPD</i> , 2017 , 12, 2001-2014	3	7
119	Evaluation of the Efficacy and Safety of Two Doses of Aclidinium and Formoterol in Fixed-Dose Combination in Patients With COPD: The ACLIFORM Study. <i>Chest</i> , 2014 , 145, 375A	5.3	7
118	Treatment Trials in Young Patients with COPD and Pre-COPD Patients: Time to Move Forward. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 ,	10.2	7
117	Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this novel, inhaled, long-acting, dual-pharmacology bronchodilator. <i>Respiratory Research</i> , 2020 , 21, 102	7.3	7
116	Effects of baseline symptom burden on treatment response in COPD. <i>International Journal of COPD</i> , 2019 , 14, 181-194	3	7
115	Daily variation in lung function in COPD patients with combined albuterol and ipratropium: results from a 4-week, randomized, crossover study. <i>Pulmonary Pharmacology and Therapeutics</i> , 2015 , 31, 85-91	3.5	6
114	Extrafine triple therapy in patients with asthma and persistent airflow limitation. <i>European Respiratory Journal</i> , 2020 , 56,	13.6	6
113	Benefits of Tiotropium/Olodaterol Compared with Tiotropium in Patients with COPD Receiving only LAMA at Baseline: Pooled Analysis of the TONADO and OTEMTO Studies. <i>Advances in Therapy</i> , 2020 , 37, 3485-3499	4.1	6
112	Bronchodilator effects, pharmacokinetics and safety of PSX1002-GB, a novel glycopyrronium bromide formulation, in COPD patients; a randomised crossover study. <i>Pulmonary Pharmacology and Therapeutics</i> , 2016 , 37, 9-14	3.5	6
111	Seretide withdrawal increases airway inflammation in moderate COPD patients. <i>European Journal of Clinical Pharmacology</i> , 2009 , 65, 1165-6	2.8	6
110	Risk of Exacerbation and Pneumonia with Single-Inhaler Triple versus Dual Therapy in IMPACT. <i>Annals of the American Thoracic Society</i> , 2021 , 18, 788-798	4.7	6
109	Bronchodilator reversibility in patients with COPD revisited: short-term reproducibility. <i>International Journal of COPD</i> , 2016 , 11, 2035-40	3	6
108	Acute cardiovascular safety of two formulations of beclometasone dipropionate/formoterol fumarate in COPD patients: A single-dose, randomised, placebo-controlled crossover study. <i>Pulmonary Pharmacology and Therapeutics</i> , 2017 , 42, 43-51	3.5	5

107	High frequency of infection of lung cancer patients with the parasite. <i>ERJ Open Research</i> , 2019 , 5,	3.5	5
106	The role of CRAC channel in asthma. <i>Pulmonary Pharmacology and Therapeutics</i> , 2015 , 35, 67-74	3.5	5
105	The systemic exposure to inhaled beclometasone/formoterol pMDI with valved holding chamber is independent of age and body size. <i>Pulmonary Pharmacology and Therapeutics</i> , 2015 , 30, 102-9	3.5	5
104	Evaluation of New Drugs for Asthma and COPD: Endpoints, Biomarkers and Clinical Trial Design. <i>Handbook of Experimental Pharmacology</i> , 2017 , 237, 243-264	3.2	5
103	Chronic Obstructive Pulmonary Disease, Neutrophils and Bacterial Infection: A Complex Web Involving IL-17 and IL-22 Unravels. <i>EBioMedicine</i> , 2015 , 2, 1580-1	8.8	5
102	Critical assessment of the value of sputum neutrophils. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2013 , 10, 107-14	2	5
101	The relationship between airway immunoglobulin activity and eosinophils in COPD. <i>Journal of Cellular and Molecular Medicine</i> , 2021 , 25, 2203-2212	5.6	5
100	Tanimilast, A Novel Inhaled Pde4 Inhibitor for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease. <i>Frontiers in Pharmacology</i> , 2021 , 12, 740803	5.6	5
99	Blood Eosinophil Counts in Chronic Obstructive Pulmonary Disease: A Biomarker of Inhaled Corticosteroid Effects. <i>Tuberculosis and Respiratory Diseases</i> , 2020 , 83, 185-194	3.2	5
98	Small airway disease in chronic obstructive pulmonary disease: insights and implications for the clinician. <i>Current Opinion in Pulmonary Medicine</i> , 2020 , 26, 162-168	3	5
97	Long-Acting Bronchodilators for Chronic Obstructive Pulmonary Disease: Which One(S), How, and When?. <i>Clinics in Chest Medicine</i> , 2020 , 41, 463-474	5.3	5
96	Outcomes Evaluated in Controlled Clinical Trials on the Management of COVID-19: A Methodological Systematic Review. <i>Life</i> , 2020 , 10,	3	5
95	Pharmacological treatment of stable chronic obstructive pulmonary disease. <i>Respirology</i> , 2021 , 26, 643-651	5.1	5
94	Type-2 airway inflammation in mild asthma patients with high blood eosinophils and high fractional exhaled nitric oxide. <i>Clinical and Translational Science</i> , 2021 , 14, 1259-1264	4.9	5
93	COPD patients with chronic bronchitis and higher sputum eosinophil counts show increased type-2 and PDE4 gene expression in sputum. <i>Journal of Cellular and Molecular Medicine</i> , 2021 , 25, 905-918	5.6	5
92	Blood eosinophil counts and the development of obstructive lung disease: the Kangbuk Samsung Health Study. <i>European Respiratory Journal</i> , 2021 , 58,	13.6	5
91	The pharmacokinetics, pharmacodynamics and tolerability of PUR0200, a novel tiotropium formulation, in chronic obstructive pulmonary disease. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 2097-2105	3.8	5
90	Triple Therapy in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 196, 1082-1083	10.2	4

89	Efficacy of aclidinium/formoterol 400/12 µg, analyzed by airflow obstruction severity, age, sex, and exacerbation history: pooled analysis of ACLIFORM and AUGMENT. <i>International Journal of COPD</i> , 2019 , 14, 479-491	3	4
88	High- and low-dose allergen challenges in asthmatic patients using inhaled corticosteroids. <i>British Journal of Clinical Pharmacology</i> , 2015 , 79, 523-32	3.8	4
87	Impact of Body Mass Index Change on the Prognosis of Chronic Obstructive Pulmonary Disease. <i>Respiration</i> , 2020 , 99, 943-953	3.7	4
86	Now We Know Who You Are: A Clear Description of Mononuclear Phagocyte Subsets in the Human Lung. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016 , 193, 594-6	10.2	4
85	Evaluation of systemic absorption and bronchodilator effect of glycopyrronium bromide delivered by nebulizer or a dry powder inhaler in subjects with chronic obstructive pulmonary disease. <i>Respiratory Research</i> , 2019 , 20, 132	7.3	4
84	Misinterpretation of time-to-first event curves can lead to inappropriate treatment. <i>European Respiratory Journal</i> , 2019 , 54,	13.6	4
83	The reproducibility of adenosine monophosphate bronchial challenges in mild, steroid-naïve asthmatics. <i>British Journal of Clinical Pharmacology</i> , 2008 , 66, 261-5	3.8	4
82	Novel anti-inflammatory treatments for asthma. <i>Expert Review of Respiratory Medicine</i> , 2008 , 2, 617-29	3.8	4
81	Tiotropium/Olodaterol Decreases Exacerbation Rates Compared with Tiotropium in a Range of Patients with COPD: Pooled Analysis of the TONADO/DYNAGITO Trials. <i>Advances in Therapy</i> , 2020 , 37, 4266-4279	4.1	4
80	Comparison of the effect of beclometasone/formoterol in asthma patients after methacholine-induced bronchoconstriction: A noninferiority study using metered dose vs. dry powder inhaler. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 729-736	3.8	4
79	Letter to the editor: indacaterol/glycopyrronium/mometasone furoate compared with salmeterol/fluticasone propionate in patients with asthma: a randomized controlled cross-over study. <i>Respiratory Research</i> , 2020 , 21, 87	7.3	4
78	Tiotropium/Olodaterol Delays Clinically Important Deterioration Compared with Tiotropium Monotherapy in Patients with Early COPD: a Post Hoc Analysis of the TONADO Trials. <i>Advances in Therapy</i> , 2021 , 38, 579-593	4.1	4
77	The novel bronchodilator navafenterol: a phase 2a, multi-centre, randomised, double-blind, placebo-controlled crossover trial in COPD. <i>European Respiratory Journal</i> , 2021 ,	13.6	4
76	Red Blood Cell-Derived Iron Alters Macrophage Function in COPD.. <i>Biomedicines</i> , 2021 , 9,	4.8	4
75	Use of concomitant inhaled corticosteroids: pooled data from two phase III studies of aclidinium plus formoterol in COPD. <i>Npj Primary Care Respiratory Medicine</i> , 2017 , 27, 13	3.2	3
74	Aclidinium bromide in fixed-dose combination with formoterol fumarate in the management of COPD: an update on the evidence base. <i>Therapeutic Advances in Respiratory Disease</i> , 2019 , 13, 1753466619850725	4.9	3
73	Research highlights from the 2018 European Respiratory Society International Congress: airway disease. <i>ERJ Open Research</i> , 2019 , 5,	3.5	3
72	Different inhaled allergen challenge models give reproducible results. <i>Pulmonary Pharmacology and Therapeutics</i> , 2015 , 33, 57-8	3.5	3

71	Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial. <i>Respiratory Research</i> , 2020 , 21, 139	7.3	3
70	ERS International Congress, Madrid, 2019: highlights from the Airway Diseases, Asthma and COPD Assembly. <i>ERJ Open Research</i> , 2020 , 6,	3.5	3
69	The efficacy of extrafine beclomethasone dipropionate-formoterol fumarate in COPD patients who are not "frequent exacerbators": a post hoc analysis of the FORWARD study. <i>International Journal of COPD</i> , 2017 , 12, 3263-3271	3	3
68	Realising the potential of various inhaled airway challenge agents through improved delivery to the lungs. <i>Pulmonary Pharmacology and Therapeutics</i> , 2018 , 49, 27-35	3.5	3
67	P189 Reduced COPD Exacerbations Associated with Acclidinium Bromide Versus Placebo: A Pooled Analysis of Phase III Data. <i>Thorax</i> , 2012 , 67, A146.1-A146	7.3	3
66	Optimum treatment for chronic obstructive pulmonary disease exacerbation prevention. <i>Annals of Translational Medicine</i> , 2016 , 4, 531	3.2	3
65	ADAM15 expression is increased in lung CD8 T cells, macrophages, and bronchial epithelial cells in patients with COPD and is inversely related to airflow obstruction. <i>Respiratory Research</i> , 2020 , 21, 188	7.3	3
64	Symptom Improvement Following Treatment with the Inhaled Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine in Patients with Moderate to Severe COPD - A Detailed Analysis. <i>International Journal of COPD</i> , 2020 , 15, 2199-2206	3	3
63	A phase 2 study of the inhaled pan-JAK inhibitor TD-0903 in severe COVID-19: Part 1		3
62	Extrafine triple therapy and asthma exacerbation seasonality: TRIMARAN and TRIGGER post hoc analyses. <i>Journal of Allergy and Clinical Immunology</i> , 2021 , 148, 262-265.e2	11.5	3
61	DuoResp Spiromax adherence, satisfaction and ease of use: findings from a multi-country observational study in patients with asthma and COPD in Europe (SPRINT). <i>Journal of Asthma</i> , 2020 , 57, 1110-1118	1.9	3
60	Remote FEV1 Monitoring in Asthma Patients: A Pilot Study. <i>Clinical and Translational Science</i> , 2021 , 14, 529-535	4.9	3
59	Prognostic value of clinically important deterioration in COPD: IMPACT trial analysis. <i>ERJ Open Research</i> , 2021 , 7,	3.5	3
58	Eosinophil-derived neurotoxin: A biologically and analytically attractive asthma biomarker. <i>PLoS ONE</i> , 2021 , 16, e0246627	3.7	3
57	Single inhaler triple therapy (SITT) in asthma: Systematic review and practice implications. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021 ,	9.3	3
56	Improvements in lung function with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler dual therapies in patients with COPD: a sub-study of the ETHOS trial. <i>Therapeutic Advances in Respiratory Disease</i> , 2021 , 15, 17534666211034329	4.9	3
55	Reproducibility of nasal allergen challenge responses in adults with allergic rhinitis. <i>Clinical Pharmacology: Advances and Applications</i> , 2019 , 11, 67-76	1.5	2
54	The TRIFLOW study: a randomised, cross-over study evaluating the effects of extrafine beclometasone/formoterol/glycopyrronium on gas trapping in COPD. <i>Respiratory Research</i> , 2020 , 21, 323	7.3	2

53	Dexamethasone and p38 MAPK inhibition of cytokine production from human lung fibroblasts. <i>Fundamental and Clinical Pharmacology</i> , 2021 , 35, 714-724	3.1	2
52	Single inhaler triple therapy with extrafine beclomethasone, formoterol, and glycopyrronium for the treatment of chronic obstructive pulmonary disease. <i>Expert Opinion on Pharmacotherapy</i> , 2018 , 19, 1279-1287	4	2
51	The reproducibility of bolus allergen challenges; power calculations for clinical trials. <i>European Journal of Clinical Pharmacology</i> , 2013 , 69, 1187-8	2.8	2
50	Inhaled Steroids and Active Smoking Drive Chronic Obstructive Pulmonary Disease Symptoms and Biomarkers to a Greater Degree Than Airflow Limitation. <i>Biomarker Insights</i> , 2017 , 12, 1177271917730306	3.5	2
49	Aclidinium bromide for the treatment of chronic obstructive pulmonary disease. <i>Expert Review of Respiratory Medicine</i> , 2012 , 6, 581-8	3.8	2
48	Cyclic hydrostatic pressure and cotton particles stimulate synthesis by human lung macrophages of cytokines in vitro. <i>Respiratory Research</i> , 2009 , 10, 44	7.3	2
47	Efficacy and safety of aclidinium/formoterol fixed-dose combination in patients with moderate to severe airflow obstruction, stratified by severity 2015 ,		2
46	Tiotropium + olodaterol fixed-dose combination shows clinically meaningful improvements in quality of life versus placebo 2015 ,		2
45	Late Breaking Abstract - Blood eosinophil counts and treatment response in COPD: analyses of IMPACT 2018 ,		2
44	Lung function normalization with indacaterol/glycopyrronium/mometasone furoate in patients with asthma 2019 ,		2
43	Lung function improvements following inhaled indacaterol/glycopyrronium/mometasone furoate are independent of dosing time in asthma patients: a randomised trial. <i>ERJ Open Research</i> , 2021 , 7,	3.5	2
42	Stability of eosinophilic inflammation in COPD bronchial biopsies. <i>European Respiratory Journal</i> , 2020 , 56,	13.6	2
41	Reply to: Re-evaluating triple ICS/LABA/LAMA therapies for COPD patients: a network meta-analysis of ETHOS, KRONOS, IMPACT, and TRILOGY studies. <i>Expert Review of Respiratory Medicine</i> , 2021 , 15, 577-578	3.8	2
40	Current developments and future directions in COPD. <i>European Respiratory Review</i> , 2020 , 29,	9.8	2
39	Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: the TRIVERSITYI randomised controlled trial. <i>Respiratory Research</i> , 2021 , 22, 90	7.3	2
38	InforMing the PATHway of COPD Treatment (IMPACT) trial: fibrinogen levels predict risk of moderate or severe exacerbations. <i>Respiratory Research</i> , 2021 , 22, 130	7.3	2
37	Effect of Age on the Efficacy and Safety of Once-Daily Single-Inhaler Triple-Therapy Fluticasone Furoate/Umeclidinium/Vilanterol in Patients With COPD: A Post Hoc Analysis of the Informing the Pathway of COPD Treatment Trial. <i>Chest</i> , 2021 , 159, 985-995	5.3	2
36	Triple Versus Dual Combination Therapy in Chronic Obstructive Pulmonary Disease in Asian Countries: Analysis of the IMPACT Trial. <i>Pulmonary Therapy</i> , 2021 , 7, 101-118	3	2

35	The Manchester Respiratory-related Sleep Symptoms scale for patients with COPD: development and validation. <i>International Journal of COPD</i> , 2018 , 13, 3885-3894	3	2
34	CONQUEST Quality Standards: For the Collaboration on Quality Improvement Initiative for Achieving Excellence in Standards of COPD Care. <i>International Journal of COPD</i> , 2021 , 16, 2301-2322	3	2
33	New Versus Old: The Impact of Changing Patterns of Inhaled Corticosteroid Prescribing and Dosing Regimens in Asthma Management.. <i>Advances in Therapy</i> , 2022 , 1	4.1	2
32	Pharmacology Versus Convenience: A Benefit/Risk Analysis of Regular Maintenance Versus Infrequent or As-Needed Inhaled Corticosteroid Use in Mild Asthma. <i>Advances in Therapy</i> , 2021 , 39, 706	4.1	2
31	Prevalence of airflow obstruction in patients attending a rapid access chest pain clinic. <i>Respiratory Medicine</i> , 2009 , 103, 736-42	4.6	1
30	Intranasal GSK2245035, a Toll-like receptor 7 agonist, does not attenuate the allergen-induced asthmatic response in a randomized, double-blind, placebo-controlled experimental medicine study. <i>PLoS ONE</i> , 2020 , 15, e0240964	3.7	1
29	Tiotropium; more knowledge leads to more questions. <i>International Journal of COPD</i> , 2008 , 3, i-ii	3	1
28	Overcoming Therapeutic Inertia to Reduce the Risk of COPD Exacerbations: Four Action Points for Healthcare Professionals. <i>International Journal of COPD</i> , 2021 , 16, 3009-3016	3	1
27	Identifying small airway dysfunction in asthma in clinical practice. <i>Jornal Brasileiro De Pneumologia</i> , 2020 , 46, e20200046	1.1	1
26	A randomised, double-blind, placebo-controlled study to evaluate the efficacy of oral azithromycin as a supplement to standard care for adult patients with acute exacerbations of asthma (the AZALEA trial). <i>Efficacy and Mechanism Evaluation</i> , 2016 , 3, 1-88	1.7	1
25	Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT Study. <i>Advances in Therapy</i> , 2020 , 37, 3775-3790	4.1	1
24	Future concepts in bronchodilation for COPD: dual- monotherapy. <i>European Respiratory Review</i> , 2021 , 30,	9.8	1
23	Letter to editor - a response to: Efficacy and safety of triple combination therapy for treating chronic obstructive pulmonary disease: an expert review? <i>Expert Opinion on Pharmacotherapy</i> , 2021 , 22, 939-941	4	1
22	The dose response of inhaled LPS challenge in healthy subjects. <i>European Journal of Inflammation</i> , 2018 , 16, 205873921878482	0.3	1
21	Assessment of bacterial exposure on phagocytic capability and surface marker expression of sputum macrophages and neutrophils in COPD patients. <i>Clinical and Experimental Immunology</i> , 2021 , 206, 99-109	6.2	1
20	A single blood eosinophil count measurement is as good as two for prediction of ICS treatment response in the IMPACT trial. <i>European Respiratory Journal</i> , 2021 , 58,	13.6	1
19	Airway Bacteria Quantification Using Polymerase Chain Reaction Combined with Neutrophil and Eosinophil Counts Identifies Distinct COPD Endotypes. <i>Biomedicine</i> , 2021 , 9,	4.8	1
18	COPD lung studies of Nrf2 expression and the effects of Nrf2 activators.. <i>Inflammopharmacology</i> , 2022 , 1	5.1	1

17	Inhaled Phosphodiesterase Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease. <i>Drugs</i> , 2021 , 81, 1821-1830	12.1	o
16	FEV recovery following methacholine challenge in asthma: Variability and comparison of methods. <i>Pulmonary Pharmacology and Therapeutics</i> , 2020 , 60, 101876	3.5	o
15	Gender specific airway gene expression in COPD sub-phenotypes supports a role of mitochondria and of different types of leukocytes. <i>Scientific Reports</i> , 2021 , 11, 12848	4.9	o
14	Aclidinium bromide/formoterol fumarate as a treatment for COPD: an update. <i>Expert Review of Respiratory Medicine</i> , 2021 , 15, 1093-1106	3.8	o
13	Inhaled triple therapy in chronic obstructive pulmonary disease - AuthorsPreply. <i>Lancet, The</i> , 2018 , 392, 1113-1114	4.0	o
12	Interclass Difference in Pneumonia Risk in COPD Patients Initiating Fixed Dose Inhaled Treatment Containing Extrafine Particle Beclometasone versus Fine Particle Fluticasone.. <i>International Journal of COPD</i> , 2022 , 17, 355-370	3	o
11	Sputum cell counts in COPD patients who use electronic cigarettes.. <i>European Respiratory Journal</i> , 2022 ,	13.6	o
10	Relationship between prior inhaled corticosteroid use and benefits of budesonide/glycopyrronium/formoterol fumarate dihydrate on exacerbations, symptoms, health-related quality of life, and lung function in patients with chronic obstructive pulmonary disease: Analyses from the ETHOS study.. <i>Respiratory Medicine</i> , 2022 , 197, 106857	4.6	o
9	Reply to Pouwels : Confounding Factors Affecting sRAGE as a Biomarker for Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019 , 200, 114-115	10.2	
8	Role of T Regulatory Cells in the Pathogenesis of Asthma: Response. <i>Chest</i> , 2010 , 138, 1283	5.3	
7	The commutability of enzyme linked immunosorbent assays for the quantification of serum eosinophil-derived neurotoxin (EDN). <i>Journal of Immunological Methods</i> , 2021 , 500, 113181	2.5	
6	Extrafine Beclometasone Dipropionate/Formoterol Fumarate vs Double Bronchodilation Therapy in Patients with COPD: A Historical Real-World Non-Inferiority Study. <i>International Journal of COPD</i> , 2020 , 15, 2739-2750	3	
5	A Comparison of the Real-Life Clinical Effectiveness of the Leading Licensed ICS/LABA Combination Inhalers in the Treatment for COPD. <i>International Journal of COPD</i> , 2020 , 15, 3093-3103	3	
4	Reply to: "Intraclass Difference in Pneumonia Risk with Fluticasone and Budesonide in COPD: A Systematic Review of Evidence from Direct-Comparison Studies" [Letter]. <i>International Journal of COPD</i> , 2021 , 16, 1299-1301	3	
3	High degree of polyclonality hinders somatic mutation calling in lung brush samples of COPD cases and controls. <i>Scientific Reports</i> , 2019 , 9, 20158	4.9	
2	New Drugs for Airway Diseases 2022 , 741-753		
1	Normalisation of airflow limitation in asthma: Post-hoc analyses of TRIMARAN and TRIGGER.. <i>Clinical and Translational Allergy</i> , 2022 , 12, e12145	5.2	